Patents by Inventor Lewis J. Gazzard

Lewis J. Gazzard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF IAP
    Publication number: 20100256115
    Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R1, R2, R3, R4, R4?, R5, R5?, R6 and R6? are as described herein.
    Type: Application
    Filed: March 18, 2010
    Publication date: October 7, 2010
    Inventors: Frederick Cohen, Kurt Deshayes, Wayne J. Fairbrother, Bainian Feng, John A. Flygare, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui
  • Acylsulfamide inhibitors of factor VIIa
    Patent number: 7250447
    Abstract: Compounds having the general formula I are useful for inhibiting serine protease enzymes, such as Tissue Factor VIIa, factor Xa, thrombin and kallikrein and have improved permeability properties.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: July 31, 2007
    Assignee: Genentech, Inc.
    Inventors: Thomas E. Rawson, Lewis J. Gazzard
  • Inhibitors of IAP
    Patent number: 7244851
    Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R1, R2, R3, R4, R4?, R5, R5?, R6 and R6? are as described herein.
    Type: Grant
    Filed: July 5, 2005
    Date of Patent: July 17, 2007
    Assignee: Genentech, Inc.
    Inventors: Frederick Cohen, Kurt Deshayes, Wayne J. Fairbrother, Bainian Feng, John A. Flygare, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui
  • Acylsulfamide inhibitors of factor VIIa
    Publication number: 20040242585
    Abstract: Compounds having the general formula I are useful for inhibiting serine protease enzymes, such as Tissue Factor VIIa, factor Xa, thrombin and kallikrein and have improved permeability properties. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Application
    Filed: May 19, 2004
    Publication date: December 2, 2004
    Inventors: Thomas E. Rawson, Lewis J. Gazzard
  • Caspase activivated prodrugs therapy
    Publication number: 20040052793
    Abstract: The invention provides novel methods for the localized delivery of pharmaceutical agents by the administration of a caspase conjugate that targets a cell type of interest and the additional administration of a pro-agent that is locally converted, in the presence of the caspase, to an active agent. The invention further provides novel tageting agents comprising a caspase as well as novel prodrugs comprising a caspase cleavable prodrug moiety.
    Type: Application
    Filed: August 2, 2002
    Publication date: March 18, 2004
    Inventors: Paul J. Carter, Lewis J. Gazzard